Therefore, basal protein expression levels from early passage Stage III derived melanoma cells was sufficient to approximate the in vitro response to the ATP-competitive MEK inhibitor, selumetinib and this was unrelated to BRAF/NRAS mutational genotype. Here, BRAF is linked to melanoma.